. Systemic concentrations of L-arginine/NO pathway metabolites: (a) arginine; (b) citrulline; (c) asymmetric dimethylarginine; (d) symmetric dimethylarginine; (e) dimethylamine. CONT, healthy controls; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; 1, significantly different from CONT; 2, significantly different from IBD; 3, significantly different from IBS. Data analyzed using Kruskal-Wallis H test and presented as medians (red triangles, numbers below dot-plots) with 95% confidence interval (whiskers). 
(e) Figure S2 . Systemic concentrations of L-arginine/NO pathway metabolites: (a) arginine; (b) citrulline; (c) asymmetric dimethylarginine; (d) symmetric dimethylarginine; (e) dimethylamine. CDa, active Crohn's disease; CDi, inactive Crohn's disease; CONT, healthy controls; IBS, irritable bowel syndrome; UCa, active ulcerative colitis; UCi, inactive ulcerative colitis; 1, significantly different from CDa; 2, significantly different from CDi; 3, significantly different from CONT; 4, significantly different from IBS; 5, significantly different from UCa; 6, significantly different from UCi. Data analyzed using Kruskal-Wallis H test and presented as medians (red triangles, numbers below dot-plots) with 95% confidence interval (whiskers). (a) 
